Renal Angiotensinogen and Sodium-Glucose Cotransporter-2 Inhibition: Insights from Experimental Diabetic Kidney Disease

American Journal of Nephrology

Volumn 49, Issue 4, 2019, Pages 328-330

  Burns, Kevin D ^a   Cherney, David ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTANE; ADENOSINE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; CANAGLIFLOZIN; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN F; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; URIC ACID; GLUCOSE; SODIUM;

ALBUMINURIA; ARTERIAL STIFFNESS; BLOOD PRESSURE; BODY WEIGHT LOSS; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; ELECTROLYTE TRANSPORT; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; EXPERIMENTAL DIABETIC NEPHROPATHY; GENE TARGETING; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLASMA VOLUME; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM URINE LEVEL; VASOCONSTRICTION; ANIMAL; DIABETIC NEPHROPATHY; HYPERTENSION; KIDNEY; MOUSE;

ANGIOTENSINOGEN; ANIMALS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLUCOSE; HYPERTENSION; KIDNEY; MICE; SODIUM;

EID: 85063651561     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000499598     Document Type: Review

References (8)

1. Woods TC, Satou R, Miyata K, et al. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus. Am J Nephrol. 2019; 49: 331-41.
2. Abdo S, Lo CS, Chenier I, Shamsuyarova A, Filep JG, Ingelfinger JR, et al. Heterogeneous nuclear ribonucleoproteins F and K mediate insulin inhibition of renal angiotensinogen gene expression and prevention of hypertension and kidney injury in diabetic mice. Diabetologia. 2013 Jul; 56(7): 1649-60.
3. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017 Oct; 136(17): 1643-58.
4. Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, et al. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother. 2018 Jul; 103: 59-66.
5. Ansary TM, Nakano D, Nishiyama A. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int J Mol Sci. 2019 Feb; 20(3): 20.
6. Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, et al. Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci. 2018 Jun; 137(2): 220-3.
7. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 Feb; 129(5): 587-97.
8. Yoshimoto T, Furuki T, Kobori H, Miyakawa M, Imachi H, Murao K, et al. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. J Investig Med. 2017 Oct; 65(7): 1057-61.